NOTCH1 and neoplasm: In particular, genetic blockade of Notch1 combined with PI3K or TORC1/2 inhibition abrogates the increase of BCSC markers, mammosphere formation, and in vivo tumor-initiating capacity, thus eradicating drug-resistant BCSCs[116].